Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland.
Expert Opin Investig Drugs. 2010 Oct;19(10):1275-95. doi: 10.1517/13543784.2010.517744.
Despite the marked development in the field of preparative regimens prior to hematopoietic stem cell transplantation (HSCT) over the last decade, the search for a superior conditioning agent is still continuing. In view of the literature reports, treosulfan (TREO), a structural analog of busulfan (BU), appears to be a promising candidate in terms of myeloablative, immunosuppressive and antimalignancy effects as well as low organ toxicity.
The article focuses on pharmacological activity, pharmacokinetics and toxicity of TREO. Compressed description of the drug-based conditioning prior to HSCT is also presented. Finally, TREO and BU characteristics are compared. Specific information of TREO concerning pediatric and adult patients is provided throughout the whole paper. The data refer predominantly to the publications, in majority from the last 10 years.
According to our best knowledge, the paper is the first such comprehensive review on TREO, especially in terms of its application in pediatric HSCT.
TREO offers a great potential as a conditioning agent prior to HSCT but further investigations of the drug are warranted to clearly verify its advantages. However, we expect TREO to be registered as a novel conditioning agent in the near future.
尽管在过去十年中，造血干细胞移植（HSCT）前的预备方案领域取得了显著的发展，但仍在继续寻找更好的调理剂。鉴于文献报道，三嗪（TREO），一种白消安（BU）的结构类似物，在骨髓清除、免疫抑制和抗恶性肿瘤作用以及低器官毒性方面似乎是一种很有前途的候选药物。
TREO 的药理学活性、药代动力学和毒性。也介绍了基于药物的 HSCT 预处理的压缩描述。最后，比较了 TREO 和 BU 的特点。整篇文章提供了 TREO 针对儿科和成人患者的具体信息。这些数据主要参考了过去 10 年的出版物，多数来自最近的出版物。
据我们所知，这篇论文是第一篇关于 TREO 的全面综述，特别是在其应用于儿科 HSCT 方面。
TREO 作为 HSCT 前的调理剂具有很大的潜力，但需要进一步研究该药物，以明确验证其优势。然而，我们预计 TREO 将在不久的将来被注册为一种新型的调理剂。
